Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 151-161

  Gums, John G ^a   Pelletier, Elise M ^b   Blumentals, William A ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b IQVIA   (United States)

^c Medical Data Analytics   (United States)

Author keywords

Hospitalization; Influenza; Oseltamivir; Otitis media; Pneumonia; Secondary complication

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; OSELTAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CONSULTATION; CONTROLLED STUDY; DRUG COST; DRUG USE; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OTITIS MEDIA; OUTCOMES RESEARCH; OUTPATIENT CARE; PNEUMONIA; PRESCRIPTION; REIMBURSEMENT; RISK REDUCTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; OTITIS MEDIA; PNEUMONIA; RETROSPECTIVE STUDIES;

EID: 39049101312     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.151     Document Type: Article

References (36)

1. Cox FM, Cobb MM, Chua WQ, et al. Cost of treating influenza in emergency department and hospital settings. Am J Manag Care 2000;6(2):205-14
2. Neuzil KM, Reed GW, Mitchel EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. J Am Med Assoc 1999;281(10):901-7
3. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999;44(Suppl B):11-5
4. Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190(8): 1369-73
5. Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996;9(Suppl 3):26-33; discussion 50-3
6. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998;48(2):85-90
7. Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig 2006;26(6):329-40
8. Lee PY, Marchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002;137(4):225-31
9. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006;118(6):2409-17
10. Keren R, Zaoutis TE, Saddlemire S, et al. Direct medical cost of influenza-related hospitalizations in children. Pediatrics 2006;118(5):e1321-7
11. Jefferson T, Demicheli V, Rivetti D, Jones M, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367(9507):303-13
12. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283(8):1016-24
13. Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326(7401): 1235
14. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282(13):1240-6
15. Matheson N, Harnden A, Perera R, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007;1:CD002744
16. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20(2):127-33
17. Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21(5):761-8
18. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163(14):1667-72
19. Barr CE, Schulman KS, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. Curr Med Res Opin 2007;23(3):523-31
20. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161(5):749-59
21. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993;153(18):2105-11
22. Avritscher EB, Cooksley CD, Geraci JM, et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer; 2007
23. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284(13):1655-63
24. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139(5 Pt 1):321-9
25. Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza - the case of otherwise healthy Danish adolescents and adults. Pharm World Sci 2004;26(6):339-45
26. Roche. Tamiflu. Summary of product characteristics. Nutley, NJ: Roche; 2006
27. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46(10):1075-9; discussion 81-90
28. Heckmann JJ, Ichimura H, Todd P. Matching as an econometric evaluation estimator: evidence from evaluating a job training programme. Rev Econ Stud 1997;64:604-54
29. Easing the burden: the challenge of managing influenza. Am J Manag Care 2000;6:S276-81
30. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342(4):225-31
31. Ciesla G, Leader S, Stoddard J. Antibiotic prescribing rates in the US ambulatory care setting for patients diagnosed with influenza, 1997-2001. Respir Med 2004;98(11):1093-101
32. Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59:437-47
33. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33
34. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003;158:280-7
35. Montalto NJ. An office-based approach to influenza: clinical diagnosis and laboratory testing. Am Fam Physician 2003;67(1):111-8
36. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51(1):123-9